0
0

Chapter 27. Psychopharmacology

Stephen Ferrando, M.D.; James Owen, Ph.D.†; James Levenson, M.D.
DOI: 10.1176/appi.books.9781585625031.621084

Sections

Excerpt

† We would like to dedicate this chapter to our friend and colleague Jim Owen, who died on Tuesday, October 5th, 2013. Jim was a profoundly dedicated and generous man whose immense knowledge, intellectual curiosity, and academic enthusiasm continue to be an inspiration to us.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
Strategies to maximize medication adherence
Anchor for Jump
Medications with clinically significant drug interactions
Anchor for Jump
Commonly used antipsychotic agents
Anchor for Jump
Antipsychotic adverse effects
Anchor for Jump
Medications used to treat extrapyramidal side effects
Anchor for Jump
Consensus guidelines for monitoring metabolic status in patients taking antipsychotic medications
Anchor for Jump
Monitoring guidelines for clozapine
Anchor for Jump
Mood stabilizers
Anchor for Jump
Signs of lithium toxicity
Anchor for Jump
Management of lithium toxicity and chronic adverse effects
Anchor for Jump
Antidepressant medications: dosing and half-life information
Anchor for Jump
Key side effects of major antidepressant drugs
Anchor for Jump
Clinical features of serotonin syndrome
Anchor for Jump
Drugs that potentiate serotonin in the central nervous system
Anchor for Jump
Hunter Serotonin Toxicity Criteria for serotonin syndrome
Anchor for Jump
Benzodiazepines, buspirone, and sedative-hypnotics
Anchor for Jump
Psychostimulants
Anchor for Jump
Cognitive enhancers
Anchor for Jump
Common drugs with significant anticholinergic effects

References

Adler LA, Spencer T, Brown TE, et al: Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 29:44–50, 2009
[PubMed]
 
Ahmadi-Abhari SA, Ghaeli P, Fahimi F, et al: Risk factors of thyroid abnormalities in bipolar patients receiving lithium: a case control study. BMC Psychiatry 3:4, 2003
[PubMed]
 
Altemus M, Occhiogrosso M: Obstetrics and gynecology, in Clinical Manual of Psychopharmacology in the Medically Ill. Edited by Ferrando SJ, Levenson JL, Owen JA. Washington, DC, American Psychiatric Publishing, 2010, pp 339–369
 
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27:596–601, 2004
[PubMed]
 
American Psychiatric Association: Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC, American Psychiatric Association, 1992
 
American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159 (4 suppl):1–50, 2002 http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1669577. Accessed April 29, 2013.
 
American Psychiatric Association: Guideline watch: practice guideline for the treatment of patients with bipolar disorder, 2nd edition, in Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium 2006. Arlington, VA, American Psychiatric Association, 2006, pp 841–849. Available at: http://psychiatryonline.org/content.aspx?bookid=28&sectionid=1682557. Accessed April 29, 2013.
 
American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd Edition. Arlington, VA, American Psychiatric Association, 2010
 
Andrade C, Sandarsh S, Chethan KB, et al: Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 71:1565–1575, 2010
[PubMed]
 
Arana GW, Goff DC, Friedman H, et al: Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 143:650–651, 1986
[PubMed]
 
Armstrong C: American College of Obstetricians and Gynecologists (ACOG) guidelines on psychiatric medication use during pregnancy and lactation. Am Fam Physician 78:772–778, 2008
[PubMed]. Available at: http://www.aafp.org/afp/2008/0915/p772.html. Accessed April 29, 2013.
 
Avenoso A, Spinà E, Campo G, et al: Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 35:335–339, 1997
[PubMed]
 
Baethge C, Blumentritt H, Berghofer A, et al: Long-term lithium treatment and thyroid antibodies: a controlled study. J Psychiatry Neurosci 30:423–427, 2005
[PubMed]
 
Baptista T, Rangel N, Fernández V, et al: Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 93:99–108, 2007
[PubMed]
 
Bendz H, Sjödin I, Aurell M: Renal function on and off lithium in patients treated with lithium for 15 years or more: a controlled prospective lithium-withdrawal study. Nephrol Dial Transplant 11:457–460, 1996
[PubMed]
 
Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121, 2002
[PubMed]
 
Blaisdell GD: Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 27:139–146, 1994
[PubMed]
 
Birks J: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev ( 1):CD005593, 2006
[PubMed]
 
Bogazzi F, Bartalena L, Brogioni S, et al: Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 84:499–503, 1999
[PubMed]
 
Bonnot O, Vollset SE, Godet PF, et al: In utero exposure to benzodiazepine: is there a risk for anal atresia with lorazepam? [in French]. Encephale 29:553–559, 2003
[PubMed]
 
Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29:64–73, 2009
[PubMed]
 
Bowden CL, Calabrese JR, Sachs G, et al: A placebo-controlled 18-month trial of lamo-tri-gine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Lamictal 606 Study Group. Arch Gen Psychiatry 60:392–400, 2003
[PubMed]
 
Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 352:1112–1120, 2005
[PubMed]
 
Brams M, Mao AR, Doyle RL: Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgrad Med 120:69–88, 2008
[PubMed]
 
Breier A, Buchanan RW, Waltrip RW II, et al: The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 10:1–7, 1994
[PubMed]
 
Bridge JA, Iyengar S, Salary CB, et al: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297:1683–1696, 2007
[PubMed]
 
Byerly MJ, DeVane CL: Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16:177–187, 1996
[PubMed]
 
Calabrese JR, Bowden CL, Sachs GS, et al: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88, 1999
[PubMed]
 
Calabrese JR, Sullivan JR, Bowden CL, et al: Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 63:1012–1019, 2002
[PubMed]
 
Calabrese JR, Bowden CL, Sachs GS, et al: A placebo-controlled 18-month trial of lamo-tri-gine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Lamictal 605 Study Group. J Clin Psychiatry 64:1013–1024, 2003
[PubMed]
 
Caroff SN: Hyperthermia associated with other neuropsychiatric drugs, in Neuroleptic Malignant Syndrome and Related Conditions, 2nd Edition. Edited by Mann SC, Caroff SN, Keck PE Jr, et al. Washington, DC, American Psychiatric Publishing, 2003a, pp 93–120
 
Caroff SN: Neuroleptic malignant syndrome, in Neuroleptic Malignant Syndrome and Related Conditions, 2nd Edition. Edited by Mann SC, Caroff SN, Keck PE Jr, et al. Washington, DC, American Psychiatric Publishing, 2003b, pp 1–44
 
Caroff SN, Mann SC, Keck PE Jr, et al: Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20:257–259, 2000
[PubMed]
 
Caykoylu A, Capoglu I, Unuvar N, et al: Thyroid abnormalities in lithium-treated patients with bipolar affective disorder. J Int Med Res 30:80–84, 2002
[PubMed]
 
Chambers CD, Johnson KA, Dick LM, et al: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010–1015, 1996
[PubMed]
 
Cohen D, Stolk RP, Grobbee DE, et al: Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 29:786–791, 2006
[PubMed]
 
Cohen LS, Altshuler LL, Harlow BL, et al: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.JAMA 295:499–507, 2006
[PubMed]
 
Cole JA, Modell JG, Haight BR, et al: Bupropion in pregnancy and the prevalence of congenital malformations. Pharmaco-epi-de-miol Drug Saf 16:474–484, 2007
[PubMed]
 
Cole N, Parker G: Cade’s identification of lithium for manic-depressive illness—the prospector who found a gold nugget. J Nerv Ment Dis 200:1101–1104, 2012
[PubMed]
 
Cooper WO, Habel LA, Sox CM, et al: ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904, 2011
[PubMed]
 
Coppola D, Russo L, Kwarta R, et al: Evaluating the postnatal experience of risperidone use during pregnancy: pregnancy and birth outcome. Drug Saf 30:247–264, 2007
[PubMed]
 
Czeisler CA, Walsh JK, Wesnes KA, et al: Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc 84:958–972, 2009
[PubMed]
 
Deodhar SD, Singh B, Pathak CM, et al: Thyroid functions in lithium-treated psychiatric patients: a cross-sectional study. Biol Trace Elem Res 67:151–163, 1999
[PubMed]
 
Devinsky O, Honigfeld G, Patin J: Clozapine-related seizures. Neurology 41:369–371, 1991
[PubMed]
 
Diav-Citrin O, Schectman S, Ornoy S, et al: Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 66:317–322, 2005
[PubMed]
 
Dolovich LR, Addis A, Vaillancourt JM, et al: Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 317:839–843, 1998
[PubMed]
 
Dunkley EJ, Isbister GK, Sibbritt D, et al: The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 96:635–642, 2003
[PubMed]
 
Dunner DL, Fieve RR: Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 30:229–233, 1974
[PubMed]
 
Einarson A, Choi J, Einarson T, et al: Incidence of major malformations in infants following antidepressant exposure in late pregnancy: results of a large prospective cohort study. Can J Psychiatry 54:242–246, 2009
[PubMed]
 
Ernst C, Goldberg J: The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 63 (suppl 4):42–55, 2002
[PubMed]
 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001
[PubMed]
 
Farrimond LE, Roberts E, McShane R: Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open 2, 2012
[PubMed]
 
Ferrando SJ, Levenson JL, Owen JA (eds): Clinical Manual of Psychopharmacology in the Medically Ill. Washington, DC, American Psychiatric Publishing, 2010
 
Findling RL, Bukstein OG, Melmed RD, et al: A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69:149–159, 2008
[PubMed]
 
Freeman MP, Freeman SA: Lithium: clinical considerations in internal medicine. Am J Med 119:478–481, 2006
[PubMed]
 
Fuller MA, Dostrow V, Gupta S, et al: Practical considerations for carbamazepine use in bipolar disorder. Expert Opin Drug Saf 5:501–509, 2006
[PubMed]
 
Gau SS, Chao PF, Lin YJ, et al: The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J Clin Psychopharmacol 28:509–517, 2008
[PubMed]
 
Gelenberg AJ, Kane JM, Keller MB, et al: Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 321:1489–1493, 1989
[PubMed]
 
Gentile S: Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 29:303–319, 2006
[PubMed]
 
Gerson SL: G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 55 (suppl B):139–142, 1994
[PubMed]
 
Giles J, Bannigan J: Teratogenic and developmental effects of lithium. Curr Pharm Des 12:1531–1541, 2006
[PubMed]
 
Glassman AH, Bigger JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death.Am J Psychiatry 158:1774–1782, 2001
[PubMed]
 
Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1366–1377, 2001
[PubMed]
 
Grünfeld JP, Rossier BC: Lithium nephrotoxicity revisited. Nat Rev Nephrol 5:270–276, 2009
[PubMed]
 
Gurrera RJ, Caroff SN, Cohen A, et al: An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 72:1222–1228, 2011
[PubMed]
 
Guy W: Abnormal Involuntary Movement Scale (AIMS), in ECDEU Assessment Manual for Psychopharmacology, Revised. Washington, DC, U.S. Department of Health, Welfare, and Education, 1976, pp 534–537
 
Habel LA, Cooper WO, Sox CM, et al: ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306:2673–2683, 2011
[PubMed]
 
Harden CL, Goldstein MA: Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 16:291–302, 2002
[PubMed]
 
Haring C, Meise U, Humpel C, et al: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl) 99 (suppl):S38–S40, 1989
[PubMed]
 
Hernandez-Diaz S, Werler M, Walker A, et al: Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 153:961–968, 2001
[PubMed]
 
Hodgkins P, Shaw M, Coghill D, et al: Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 21:477–492, 2012
[PubMed]
 
Holmes L, Baldwin E, Smith C, et al: Increased frequency of isolated cleft palate in infants exposed to lamotrigine. Neurology 70:2152–2158, 2008
[PubMed]
 
Horowitz S, Patwardhan R, Marcus E: Hepatotoxic reactions associated with car-ba-maz-epine therapy. Epilepsia 29:149–154, 1988
[PubMed]
 
Hussain A, Burke J: Mirtazapine associated with recurrent pancreatitis—a case report. J Psychopharmacol 22:336–337, 2008
[PubMed]
 
Joffe H, Cohen LS, Suppes T, et al: Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 59:1078–1086, 2006
[PubMed]
 
Johnston AM, Eagles JM: Lithium-associated clinical hypothyroidism: prevalence and risk factors. Br J Psychiatry 175:336–339, 1999
[PubMed]
 
Juric S, Newport DJ, Ritchie JC, et al: Zolpidem (Ambien) in pregnancy: placental passage and outcome. Arch Womens Ment Health 12:441–446, 2009
[PubMed]
 
Justo D, Prokhorov V, Heller K, et al: Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 111:171–176, 2005
[PubMed]
 
Keck PE Jr, McElroy SL, Tugrul KC, et al: Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 54:305–308, 1993
[PubMed]
 
Ketter TA, Wang PW, Chandler RA, et al: Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. J Clin Psychiatry 66:642–645, 2005
[PubMed]
 
Kinon BJ, Gilmore JA, Liu H, et al: Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28 (suppl 2):55–68, 2003
[PubMed]
 
Klein DJ, Cottingham EM, Sorter M, et al: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163:2072–2079, 2006
[PubMed]
 
Kleiner J, Altshuler L, Hendrick V, et al: Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 60:249–255, 1999
[PubMed]
 
Kollins SH, Jain R, Brams M, et al: Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 127:e1406–e1413, 2011
[PubMed]
 
Kuehn BM: FDA: antipsychotics risky for elderly. JAMA 300:379–380, 2008
[PubMed]
 
Kumar R: Approved and investigational uses of modafinil: an evidence-based review. Drugs 68:1803–1839, 2008
[PubMed]
 
Kusalic M, Engelsmann F: Effect of lithium maintenance therapy on thyroid and parathyroid function. J Psychiatry Neurosci 24:227–233, 1999
[PubMed]
 
Lader M: Benzodiazepines revisited—will we ever learn? Addiction 106:2086–2109, 2011
[PubMed]
 
Lamberg TS, Kivisto KT, Neuvonen PJ: Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 63:640–645, 1998
[PubMed]
 
Lamictal (lamotrigine) package insert. Research Triangle Park, NC, Glaxo-Smith-Kline, 2012
 
Lees G, Leach MJ: Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 612:190–199, 1993
[PubMed]
 
Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, second edition. American Psychiatric Association Steering Committee on Practice Guidelines. Am J Psychiatry 161 (2 suppl):1–56, 2004
[PubMed]
 
Lewis SW, Barnes TR, Davies L, et al: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32:715–723, 2006
[PubMed]
 
Lieberman JA, Saltz BL, Johns CA, et al: The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503–510, 1991
[PubMed]
 
Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. N Engl J Med 353:1209–1223, 2005
[PubMed]
 
Liu J, Wang LN: Ramelteon in the treatment of chronic insomnia: systematic review and meta-analysis. Int J Clin Pract 66:867–873, 2012
[PubMed]
 
Maarbjerg K, Vestergaard P, Schou M: Changes in serum T4 (T4) and serum thyroid stimulating hormone (TSH) during prolonged lithium treatment. Acta Psychiatr Scand 75:217–221, 1987
[PubMed]
 
Mackin P: Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23:3–14, 2008
[PubMed]
 
Manu P, Sarpal D, Muir O, et al: When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 134:180–186, 2012
[PubMed]
 
May DE, Kratochvil CJ: Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 70:15–40, 2010
[PubMed]
 
McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610, 2006
[PubMed]
 
McIntyre RS, Panjwani ZD, Nguyen HT, et al: The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 4:281–285, 2008
[PubMed]
 
McKean A, Monasterio E: Off-label use of atypical antipsychotics: cause for concern? CNS Drugs 26:383–389, 2012
[PubMed]
 
McKenna K, Koren G, Tetelbaum M, et al: Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 66:444–449, 2005
[PubMed]
 
McShane R, Areosa SA, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev ( 2):CD003154, 2006
[PubMed]
 
Meador K, Reynolds M, Crean S, et al: Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81:1–13, 2008
[PubMed]
 
Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 55 (suppl B):47–52, 1994
[PubMed]
 
Merrill DB, Dec GW, Goff DC: Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 25:32–41, 2005
[PubMed]
 
Mills KC: The serotonin syndrome: a clinical update. Crit Care Clin 13:763–783, 1997
[PubMed]
 
Mir A, Shivakumar K, Williamson RJ, et al: Change in sexual dysfunction with ari-pip-ra-zole: a switching or add-on study. J Psychopharmacol 22:244–253, 2008
[PubMed]
 
Mizukami Y, Michigishi T, Nonomura A, et al: Histological features of the thyroid gland in a patient with lithium induced thyrotoxicosis. J Clin Pathol 48:582–584, 1995
[PubMed]
 
Moses-Kolko E, Bogen D, Perel J, et al: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293:2372–2383, 2005
[PubMed]
 
Nasrallah H: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28:83–96, 2003
[PubMed]
 
Newport D, Viguera A, Beach A, et al: Lith-ium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 162:2162–2170, 2005
[PubMed]
 
Newport J, Calamaras MR, DeVane L, et al: Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164:1214–1220, 2007
[PubMed]
 
Nurnberg HG, Hensley PL, Heiman JR, et al: Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 300:395–404, 2008
[PubMed]
 
Oberlander T, Warburton W, Misri S, et al: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898–906, 2006
[PubMed]
 
Oberlander T, Warburton W, Misri S, et al: Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83:68–76, 2008
[PubMed]
 
O’Keane V, Meaney AM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 25:26–31, 2005
[PubMed]
 
Ornoy A, Zvi N, Arnon J, et al: The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 25:388–389, 2008
[PubMed]
 
Owen JA: Alternate routes of drug administration, in Clinical Manual of Psychopharmacology in the Medically Ill. Edited by Ferrando SJ, Levenson JL, Owen JA. Washington, DC, American Psychiatric Publishing, 2010a, pp 79–99
 
Owen JA: Pharmacokinetics, pharmacodynamics, and principles of drug interactions, in Clinical Manual of Psychopharmacology in the Medically Ill. Edited by Ferrando SJ, Levenson JL, Owen JA. Washington, DC, American Psychiatric Publishing, 2010b, pp 3–38
 
Ozdemir V, Bertilsson L, Miura J, et al: CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 17:339–347, 2007
[PubMed]
 
Ozpoyraz N, Tamam L, Kulan E: Thyroid abnormalities in lithium-treated patients. Adv Ther 19:176–184, 2002
[PubMed]
 
Paul R, Minay J, Cardwell C, et al: Meta-analysis of the effects of lithium usage on serum creatinine levels. J Psychopharmacol 24:1425–1431, 2010
[PubMed]
 
Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, et al: Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226–237, 1990
[PubMed]
 
Pellock JM, Willmore LJ: A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 41:961–964, 1991
[PubMed]
 
Pellock JM, Wilder BJ, Deaton R, Sommerville KW: Acute pancreatitis coincident with valproate use: a critical review. Epi-lepsia 43:1421–1424, 2002
[PubMed]
 
Perlis RH, Sachs GS, Lafer B, et al: Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 159:1155–1159, 2002
[PubMed]
 
Perry PJ, Miller DD, Arndt SV, et al: Cloza-pine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231–235, 1991
[PubMed]
 
Presne C, Fakhouri F, Noel LH, et al: Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int 64:585–592, 2003
[PubMed]
 
Rasimas JJ: Medical toxicology, in The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, 2nd Edition. Edited by Levenson JL. Washington, DC, American Psychiatric Publishing, 2011, pp 929–953
 
Ray WA, Chung CP, Murray KT, et al: Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360:225–235, 2009
[PubMed]
 
Reis M, Kallen B: Maternal use of antipsychotic in early pregnancy and delivery outcome. J Clin Psychopharmacol 28:279–288, 2008
[PubMed]
 
Robinson DS, Amsterdam JD: The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord 105:15–23, 2008
[PubMed]
 
Rochon PA, Normand S-L, Gomes T, et al: Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 168:1090–1096, 2008
[PubMed]
 
Rolinski M, Fox C, Maidment I, et al: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev ( 3):CD006504, 2012
[PubMed]
 
Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289, 2003
[PubMed]
 
Sackeim HA, Haskett RF, Mulsant BH, et al: Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 285:1299–1307, 2001
[PubMed]
 
Sallee FR, Eaton K: Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD). Expert Opin Pharmacother 11:2549–2556, 2010
[PubMed]
 
Sallee FR, McGough J, Wigal T, et al: Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155–165, 2009
[PubMed]
 
Sankar R: GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 26:229–244, 2012
[PubMed]
 
Saunders BD, Saunders EF, Gauger PG: Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 33:2314–2323, 2009
[PubMed]
 
Schachar R, Ickowicz A, Crosbie J, et al: Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 18:11–24, 2008
[PubMed]
 
Schatzberg AF, Nemeroff CB (eds): The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition. Washington, DC, American Psychiatric Publishing, 2009
 
Schatzberg AF, Haddad P, Kaplan EM, et al: Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry 58 (suppl 7):5–10, 1997
[PubMed]
 
Schmitt KC, Reith ME: The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 6:e25790, 2011
[PubMed]
 
Schweitzer I, Maguire K, Ng C: Sexual side-effects of contemporary antidepressants: review. Aust N Z J Psychiatry 43:795–808, 2009
[PubMed]
 
Serri O, Li L, Mamputu JC, et al: The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370, 2006
[PubMed]
 
Shapiro PA: Cardiovascular disorders, in Clinical Manual of Psychopharmacology in the Medically Ill. Edited by Ferrando SJ, Levenson JL, Owen JA. Washington, DC, American Psychiatric Publishing, 2010, pp 181–212
 
Simko J, Horacek J: Carbamazepine and risk of hypothyroidism: a prospective study. Acta Neurol Scand 116:317–321, 2007
[PubMed]
 
Soares-Weiser K, Maayan N, McGrath J: Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev ( 2):CD000209, 2011
[PubMed]
 
Spencer TJ, Greenbaum M, Ginsberg LD, et al: Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19:501–510, 2009
[PubMed]
 
Sternbach H: The serotonin syndrome. Am J Psychiatry 148:705–713, 1991
[PubMed]
 
Stewart DE: Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 47:375–377, 2002
[PubMed]
 
Stöllberger C, Huber JO, Finsterer J: Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 20:243–251, 2005
[PubMed]
 
Stone M, Laughren T, Jones ML, et al: Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339:b2880, 2009 (published online)
[PubMed]
 
Stowell CP, Barnhill JW: Acute mania in the setting of severe hypothyroidism. Psychosomatics 46:259–261, 2005
[PubMed]
 
Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 164:870–876, 2007
[PubMed]
 
Tarsy D, Lungu C, Baldessarini RJ: Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 100:601–616, 2011
[PubMed]
 
Terzano MG, Rossi M, Palomba V, et al: New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 26:261–282, 2003
[PubMed]
 
Trileptal (oxcarbazepine) package insert. East Hanover, NJ, Novartis Pharmaceuticals Corp, March 2013
 
Trivedi MH, Fava M, Wisniewski SR, et al: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252, 2006
[PubMed]
 
Tsai G, Goff D, Chang R, et al: Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 9:1207–1213, 1998
[PubMed]
 
Tworoger SS, Hankinson SE: Prolactin and breast cancer risk. Cancer Lett 243:160–169, 2006
[PubMed]
 
U.S. Department of Health and Human Services, National Toxicology Program, Center for the Evaluation of Risks to Human Reproduction: NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines (NIH Publ No 05-4474). 2005. Available at: http://cerhr.niehs.nih.gov/chemicals/stimulants/amphetamines/AmphetamineMonograph.pdf. Accessed November 13, 2009.
 
U.S. Food and Drug Administration: FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs—FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). January 10, 2013a. Available at: http://www.fda.gov/drugs/drugsafety/ucm334033.htm. Accessed April 29, 2013.
 
U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. May 14, 2013b. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm352085.htm. Accessed September 29, 2013.
 
van Harten PN, Tenback DE: Tardive dyskinesia: clinical presentation and treatment. Int Rev Neurobiol 98:187–210, 2011
[PubMed]
 
Vasudev A, Macritchie K, Vasudev K, et al: Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev ( 12):CD004857, 2011
[PubMed]
 
Vieweg WV, Hasnain M, Howland RH, et al: Citalopram, QTc interval prolongation, and torsade de pointes: how should we apply the recent FDA ruling? Am J Med 125:859–868, 2012
[PubMed]
 
Viguera A, Whitfield T, Baldessarini R, et al: Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 164:1817–1824, 2007
[PubMed]
 
Weisler RH, Kalali AH, Ketter TA, et al: A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 65:478–484, 2004
[PubMed]
 
Weisler RH, Keck PE Jr, Swann AC, et al: Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 66:323–330, 2005
[PubMed]
 
Wetzel H, Anghelescu I, Szegedi A, et al: Pharmacokinetic interactions of cloza-pine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2–9, 1998
[PubMed]
 
Whyte IM, Dawson AH, Buckley NA: Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96:369–374, 2003
[PubMed]
 
Wikner B, Stiller C, Bergman U, et al: Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 16:1203–1210, 2007
[PubMed]
 
Wilson R, Souza L, Sarkar N, et al: New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 59:1–6, 2002
[PubMed]
 
Windgassen K, Wesselmann U, Schulze Mönking H: Galactorrhea and hyper-pro-lac-tin-emia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology 33:142–146, 1996
[PubMed]
 
Wisner K, Sit D, Hanusa B, et al: Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 166:557–566, 2009
[PubMed]
 
Wu RR, Zhao JP, Guo XF, et al: Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 165:352–358, 2008
[PubMed]
 
Wynn G, Oesterheld J, Cozza K, et al: Clinical Manual of Drug Interaction Principles for Medical Practice. Washington, DC, American Psychiatric Publishing, 2008
 
Wyszynski D, Nambisan M, Surve T, et al: Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64:961–965, 2005
[PubMed]
 
Yonkers KA, Wisner KL, Stowe Z, et al: Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161:608–620, 2004
[PubMed]
 
Zamani A, Omrani GR, Nasab MM: Lithium’s effect on bone mineral density. Bone 4:331–334, 2009
[PubMed]
 
Zubenko GS, Cohen BM, Lipinski JF: Comparison of metoprolol and propranolol in the treatment of lithium tremor. Psychiatry Res 11:163–164, 1984
[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 6.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 7.  >
Topic Collections
Psychiatric News
PubMed Articles
Community adherence to schizophrenia treatment and safety monitoring guidelines. J Nerv Ment Dis 2014;202(1):6-12.doi:10.1097/NMD.0000000000000093.
Strategies to prevent the neuropsychiatric side-effects of corticosteroids: a case report and review of the literature. Curr Opin Organ Transplant 2014;19(2):201-8.doi:10.1097/MOT.0000000000000065.
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation